Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2024
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
CYTALUXâ„¢for the Intraoperative Imaging of Prostate Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Feasibility of Intraoperative Visualization With Cytalux in Children
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2024
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : On Target Laboratories
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cytalux (pafolacianine) is an FDA-approved optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.
Product Name : Cytalux
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 05, 2022
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 27, 2020
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
June 08, 2017
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Medelis
Deal Size : Inapplicable
Deal Type : Inapplicable
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
August 19, 2016
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Medelis
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 16, 2014
Lead Product(s) : Pafolacianine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable